Business Results for The First Quarter of FY2018 (Three-month period ended June 30, 2018) July 31, 2018

Transcription

1 Business Results for The First Quarter of FY218 (Three-month period ended June 3, 218) July 31, 218

2 Please be aware of the following: * The financial information provided on this material has been prepared in accordance with Japanese GAAP in principle. * Figures and ratio in this material are rounded to the appropriate unit in principle, and the sums of the individual figures in each table do not always correspond to the total, because of rounding. * Abbreviations: CLT: Clinical Laboratory Testing (business) HR: Healthcare Related (business) : Operating income IVD: In Vitro Diagnostics (business) Ord. income: Ordinary income Exchange rate: FY217 :1USD = JPY 1EURO = JPY FY218 :1USD = 19.8JPY 1EURO = 13.6JPY 1

3 Transition of Consolidated Sales (excl. CLT Global) FY14 FY15 FY16 FY18 2

4 Breakdown of sales (excl. CLT Global) CLT Japan IVD HR Exchange FY18 impact 3

5 Transition of Consolidated Op. Income (excl. CLT Global) FY14 FY15 FY16 FY18 4

6 Breakdown of Op. Income (excl. CLT Global) CLT IVD HR Miraca Exchange Other FY18 Japan impact factors Other factors: Improvement of facilities, optimization of operations, consulting expenses, etc. :.93 billion, 2Q:.4 billion (estimation) Estimated as unlikely to occur in the second half of FY18 5

7 Quarterly transition (excl. CLT Global) Both Net sales and increased compared to the previous quarter (4Q/FY217) Net sales Net sales Q 3Q 4Q 2Q 3Q 4Q 2Q 3Q 4Q FY15 FY16 FY 18 6

8 Transition of Consolidated EBITDA (excl. CLT Global) FY14 FY15 FY16 FY18 EBITDA = Operating income + Depreciation + Amortization of goodwill 7

9 Transition of Consolidated Ord. Income FY14 FY15 FY16 Main factors for non-operating losses FY217 FY218 FY18 Share of loss of entities accounted for using equity method -.2bn Share of loss of entities accounted for using equity method -.5bn 8

10 Transition of Consolidated Net Profit FY14 FY15 FY16 Main factors for extraordinary losses FY217 FY218 FY18 (Nothing in particular) Provision for compensation loss (Influenced by exchange rate fluctuations) -.3bn 9

11 Comparison with /FY217 (excl. CLT Global) /FY217 2Q/ 3Q/ 4Q/ FY217 FY217 FY217 /FY218 Variation Net Sales % CLT Japan % IVD % HR % 1 Op. Income % % % 3 3 CLT Japan % % % IVD % % % HR % % % 2 EBITDA % % % 1. includes Miraca Holdings and Miraca Research institute, and segmentation adjustments 2. EBITDA = Operating income + Depreciation + Amortization of goodwill 3. Small blue figures shown in the upper right corners are the individual profit margins 1

12 CLT Japan (Comparison with ) Net sales Q Off-site Testing 1.2 3Q Q FY18 FMS/Branch Lab Net sales : +.4 : -1.8 Increase in # of tests: +7.7% Acquisition of new accounts Price cut impact: -3.2% Price revision demands from clients (hospitals) Continue business growth by market share expansion and optimization of operations Net sales FMS/Branch Lab (+.13, +2.8%) Sales contribution by clients acquired during previous year Off-site testing (+.23, +1.1%) Growth in new test item and in the medical check-up market Cost increase in depreciation expenses, personnel costs etc. Other factors 11

13 IVD Net sales Q Lumipulse Others 3Q 4Q OEM etc. FY Net sales (Comparison with ) Net sales : -.4 : -1.2 Lumipulse Organic reagent sales steadily increased Japan: +7% (due to increase in # of large size instruments) Decrease in # of blood donors resulted in sales decline in JRC business OEM & Raw Material Supply Postponement within this FY Others Termination of existing overseas products Sales decrease in POCT Increase in R&D expenses, personnel costs etc. Other factors 12

14 HR Net sales Net sales : -.2 : (Comparison with ) Sterilizing Net sales: +.5, : Clinical Trials Net sales: -.16, : -.7 Business structure shift to clinical research support business, which has a longer period between receiving orders and sales contribution Deconsolidation of Asmo Clinical Pharmacology Laboratories 2Q Sterilizing 3Q FY18 4Q Clinical Trials. Others Net sales: -.7, :-.14 Others 13

15 KPI CLT business FY218 1 FY217 full year Net # of FMS/Branch lab clients Net # of GP clients IVD business Lumipulse Japan (Net # of instruments) Global Intra-group transactions (billion yen) Each figure shows net increase/decrease at the end of quarter compared to the end of last fiscal year 2 Net increase/decrease # of instruments at sites of clients and group companies 14

16 Appendix 15

17 Comparison with /FY217 (incl. CLT Global) /FY217 /FY218 Variation Net Sales % CLT % IVD % HR % Op. Income % % % CLT % % % IVD % % % HR %.5 7.6% % Ord. Income % % % Profit/loss attributable to owners of parent % % % EBITDA % % % 3 1. includes Miraca Holdings and Miraca Research Institute, and segmentation adjustments ( : -.13, FY18 : -.42) 2. EBITDA = Operating income + Depreciation + Amortization of goodwill 3. Small blue figures shown in the upper right corners are the individual profit margins 16

18 Contact information IR/SR Department mhd.ir@miraca.com Disclaimer regarding forward-looking statement: The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors. Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products. 17